[Should coronary patients chronically taking a low-dose of aspirin receive gastroprotective agents?].
The use of low-dose aspirin (75-300 mg/day) is associated with an increased risk of gastrointestinal bleeding, which is lower than that observed with common NSAIDs. Risk factors for the development of GI bleeding in patients taking low-dose aspirin are not well defined, although patients with a previous history of peptic ulcer, concomitant NSAID use and serious diseases should receive gastroprotection. Among the available drugs, proton pump inhibitors associated, when present, to Helicobacter pylori erradication, have shown the highest efficacy. The best cost-effectiveness treatment is still undefined.